Form 4: Orchestra BioMed Director David Pacitti Awarded Significant Equity Compensation

Orchestra BioMed Holdings, Inc. Director David Pacitti received an award of 12,422 restricted stock units and 36,797 stock options on June 24, 2025, as part of his compensation.

Summary

• David Pacitti, a Director of Orchestra BioMed Holdings, Inc. (OBIO), was granted equity awards on June 24, 2025.
• The awards include 12,422 shares of Common Stock in the form of Restricted Stock Units (RSUs), granted at a price of $0.
• He also received 36,797 stock options with an exercise price of $3.22 per share.
• Both the RSUs and stock options will vest in a single installment on the earlier of June 24, 2026 (one year anniversary of the grant date) or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent on his continuous service.
• Following these transactions, Mr. Pacitti beneficially owns 29,968 shares of Common Stock and 36,797 stock options.
• The stock options have an expiration date of June 24, 2035.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity compensation award to a director, which is generally positive as it aligns management's interests with shareholders. It does not contain any negative news or unexpected events, reflecting a neutral to slightly positive sentiment.

Positives

• The award of restricted stock units and stock options to Director David Pacitti aligns his interests with those of shareholders, incentivizing long-term performance.
• The vesting schedule, tied to continuous service, promotes retention of key leadership within the company.

Negatives

• No direct negatives are apparent from this Form 4 filing, which primarily reports a routine compensation event.

Risks

• No specific risks are detailed in this Form 4 filing, which is a disclosure of insider transactions and not a comprehensive risk assessment document.

Future Outlook

The Restricted Stock Units and stock options are forward-looking compensation, set to vest in one installment on the earlier of June 24, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent on the Director's continuous service to the company.

Industry Context

The granting of equity awards such as restricted stock units and stock options to directors is a common practice across various industries, particularly in biotechnology and healthcare, to align leadership incentives with shareholder value creation and to attract and retain talent. This filing reflects a standard component of executive and director compensation packages.

Comparison to Industry Standards

• The specific value and structure of these equity awards would typically be benchmarked against compensation practices for directors at peer companies within the biotechnology or medical device sector, considering factors like company size, stage of development, and market capitalization. Without specific peer compensation data, a direct comparison to industry standards is not feasible from this document alone.

Related Party Transactions

• The award of restricted stock units and stock options to David Pacitti, a Director of Orchestra BioMed Holdings, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The equity awards align the Director's financial interests with those of shareholders, potentially fostering long-term value creation and improved company performance.
• Management: The awards serve as an incentive and retention tool for the Director, reinforcing commitment to the company's success.

Next Steps

• Vesting of 12,422 Restricted Stock Units on the earlier of June 24, 2026, or the Issuer's 2026 Annual Meeting of Stockholders, subject to continuous service.
• Vesting of 36,797 Stock Options on the earlier of June 24, 2026, or the Issuer's 2026 Annual Meeting of Stockholders, subject to continuous service.
• Potential exercise of stock options by the expiration date of June 24, 2035.

Key Dates

Keywords

Orchestra BioMed, OBIO, David Pacitti, SEC Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Director Compensation